All News

sperm

Methotrexate - an old trusted friend who deserves better

Antoni Chan, MD, PhD

Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2023 – Day 4 Report

Jack Cush, MD

Day 4 was a half day closeout to the EULAR 2023 Congress.

Read Article
Magnifying glass

Clinically suspect arthralgias: justified or artefact?

David Liew, FRACP

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.

Read Article
Target,T2T,bullseye

Targeted therapies in Sjogren’s syndrome: are we close?

Md Yuzaiful Md Yusof, MRCP(UK), PhD

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.

 

Read Article
exhibitor.floor.ACR

EULAR 2023 – Day 3 Report

Jack Cush, MD

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article
38420215_s.jpg

RA and cancer risk in the biologic era

Aurelie Najm, MD, PhD

A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.

Read Article
pregnant, pregnancy, mother, fertility

Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas

Bella Mehta, MBBS, MS

Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.

Read Article
CV and Cancer Risk with JAK inhibitors Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy. https://t.co/SZLohnNEa1 https://t.co/ZEv0Q2NSBf

Links:

Dr. John Cush RheumNow ( View Tweet)
An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR23 – Day 2 Report Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations. https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA

Links:

Dr. John Cush RheumNow ( View Tweet)
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation. The better we can predict these patients, the more we can get the right therapy early POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
David Liew drdavidliew ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
New 2023 @eular_org SLE recommendations Key changes, in response to evidence: - more caution re: steroids - biologics earlier - combo therapy (BEL or CNI/VCS) considered for lupus nephritis #EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew drdavidliew ( View Tweet)
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i
Bella Mehta bella_mehta ( View Tweet)
Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY
David Liew drdavidliew ( View Tweet)
An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL

Links:

Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS #EULAR2023 poster https://t.co/dgGY496dbh
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Factors related to having a flare of arthritis during COVID-19 include female gender, higher disease activity, no DMARD at time of vaccination. Stopping DMARDs need to be weighed up against risk of flares, Pedro Machado, COVID-19 #EULAR2023 @RheumNow https://t.co/3sd32tF2kW
Dr. Antoni Chan synovialjoints ( View Tweet)
Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r
Dr. Antoni Chan synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×